Refreshed just now
Senate bill S. 5812 would permanently extend HHS authority to award priority review vouchers for rare pediatric disease products, and was referred to the HELP Committee on 2026-11-19.
Why it’s here: A federal bill extending FDA priority review vouchers for rare pediatric disease products is direct federal policy on biotechnology regulation and innovation incentives, squarely within the Biotechnology area despite the source's energy specialty.
Trace across the boardItem
3d agoCongressCommittee on Health, Education, Labor, and PensionsSenate bill S. 5812 would permanently extend HHS authority to award priority review vouchers for rare pediatric disease products, and was referred to the HELP Committee on 2026-11-19.S. 5812BiotechDetails5 linked
Connected
5 links- NewsSanders warns Democrats about spending too much time investigating TrumpBoth involve Senate Committee on Health, Education, Labor, and Pensions (HELP), Department of Health and Human Services
- HillBusiness meeting to consider the nominations of Mark Priebe, of Virginia, to be Inspector General, Department of Education, Michael Doyle, of Pennsylvania, to be a Member of the Occupational Safety and Health Review Commission, and Catherine Eschbach, of Texas, to be General Counsel of the Equal Employment Opportunity Commission.Both involve Senate Committee on Health, Education, Labor, and Pensions (HELP)
- HillS. 1387: National Biotechnology Initiative Act of 2025Both involve Senate Committee on Health, Education, Labor, and Pensions (HELP)
- NewsWhite House pulls FDA nominee Heidi Overton after wavering support from Senate RepublicansBoth involve Senate Committee on Health, Education, Labor, and Pensions (HELP)
- HillH.R. 10857: Faster Clinical Trials ActBoth involve Federal Food, Drug, and Cosmetic Act
About
- Senate Committee on Health, Education, Labor, and Pensions (HELP)
- Department of Health and Human Services